InvestorsHub Logo
Followers 140
Posts 11663
Boards Moderated 0
Alias Born 03/15/2011

Re: vinmantoo post# 267390

Sunday, 06/26/2016 6:48:50 PM

Sunday, June 26, 2016 6:48:50 PM

Post# of 346360
vinmantoo, of course there is evidence. 60% SOC improvement in PII NSCLC. While the others, the PS receptor approach, have no such results at all.


So the PS receptor targeting is worse then 'repeatedly' because it is ALWAYS and Bavi NEVER failed in combination with I-O. Furthermore MSK, NCCN, AstraZeneca (and possible Merck - we need to know if Bavi is just combined with KeyTruda or if MRK themselves are involved) are working with Bavi in IO and not with TIM's (1,3,4) TAM's (Axl, Her, etc) or any of the others at all or in that extend for combo's.

Peregrine Pharmaceuticals the Microsoft of Biotechnology! All In My Opinion. I am not advising anything, nor accusing anyone.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News